New England Research Management Lowers stake in Merck & Co. (MRK)

Merck & Co. (MRK) : New England Research Management reduced its stake in Merck & Co. by 1.29% during the most recent quarter end. The investment management company now holds a total of 38,124 shares of Merck & Co. which is valued at $2,211,192 after selling 500 shares in Merck & Co. , the firm said in a disclosure report filed with the SEC on Jul 5, 2016.Merck & Co. makes up approximately 1.93% of New England Research Management’s portfolio.

Other Hedge Funds, Including , Pensionfund Dsm Netherlands added MRK to its portfolio by purchasing 145,500 company shares during the most recent quarter which is valued at $8,439,000. Merck & Co. makes up approx 1.13% of Pensionfund Dsm Netherlands’s portfolio.Cacti Asset Management reduced its stake in MRK by selling 625 shares or 0.1% in the most recent quarter. The Hedge Fund company now holds 607,594 shares of MRK which is valued at $35,203,996. Merck & Co. makes up approx 3.82% of Cacti Asset Management’s portfolio.Cullinan Associates Inc boosted its stake in MRK in the latest quarter, The investment management firm added 4,050 additional shares and now holds a total of 231,161 shares of Merck & Co. which is valued at $13,393,468. Merck & Co. makes up approx 1.09% of Cullinan Associates Inc’s portfolio.

Merck & Co. closed down -0.01 points or -0.02% at $59.34 with 73,36,741 shares getting traded on Monday. Post opening the session at $59.26, the shares hit an intraday low of $59.2 and an intraday high of $59.75 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

On the company’s financial health, Merck & Co. reported $0.89 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on May 5, 2016. Analyst had a consensus of $0.85. The company had revenue of $9312.00 million for the quarter, compared to analysts expectations of $9445.10 million. The company’s revenue was down -1.2 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.85 EPS.

Merck & Co. Inc. is a global health care company. The Company offers health solutions through its prescription medicines vaccines biologic therapies and animal health products which it markets directly and through its joint ventures. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents generally sold by prescription for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers hospitals government agencies and managed health care providers. The Animal Health segment discovers develops manufactures and markets animal health products including vaccines. The Company’s animal health products are sold to veterinarians distributors and animal producers.

Leave a Reply

Merck & Co. - Is it time to Sell?

Top Brokerage Firms are advising their investors on Merck & Co.. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.